
What Comes After Wegovy and Zepbound? CagriSema and Retatrutide Are Two Names to Know
It is easy to think of weight-management medications as a straight line: first semaglutide, then tirzepatide, then whatever drug produces an even bigger percentage on the scale.
I do not think the next chapter is going to be that simple.
Two of the medications I am watching most closely—CagriSema and retatrutide—show why. They are not just trying to make the same mechanism stronger. They represent different ideas about which hormone systems can be combined and what that might mean for obesity treatment.
CagriSema brings amylin into the spotlight
CagriSema combines semaglutide with cagrilintide. That matters because cagrilintide is an amylin analogue, not another incretin. Amylin participates in meal-related satiety, and the combination creates a GLP-1-plus-amylin strategy.
The Phase 3 REDEFINE program has shown substantial weight reduction, and newer 2026 analyses are looking beyond the scale at questions such as appetite, food-related brain responses, visceral fat, organ fat, and body composition. That broader view is where this field is becoming especially interesting.
Retatrutide pushes multi-receptor therapy further
Retatrutide combines GIP, GLP-1, and glucagon receptor activity in one molecule. Its pivotal obesity trial reported 28.3% average weight reduction at 80 weeks with the 12 mg dose, and additional Phase 3 studies have now reported positive topline results in people with type 2 diabetes and in people with severe obesity plus established cardiovascular disease.
The next question may be “which pathway?”
As more medications reach late-stage development, I think the conversation will gradually change. Instead of asking only which medication produces the largest average weight loss, we will have better questions to ask.
How does a medication affect hunger and food noise? What happens to visceral fat and lean mass? What metabolic conditions does a patient have? What dose can that individual comfortably maintain? How durable is the response? And could one mechanism fit a particular patient’s biology better than another?
The FDA story is moving quickly
CagriSema has reached FDA review, while retatrutide has reached the final development work leading toward a planned U.S. submission. Those milestones can change quickly, which is one reason I like following this field as the news develops rather than treating any one article as the final word.
The most exciting part is not simply that new medications are coming. It is that researchers are learning how many different biological levers can be used to treat obesity as the complex chronic disease it is.




Comments